A delisting notice can follow a bankruptcy filing, not precede it

The record

Virgin Orbit Holdings, Inc., a satellite-launch company that reached public markets through a 2021 combination with the SPAC NextGen Acquisition Corporation II, filed a voluntary Chapter 11 petition in the U.S. Bankruptcy Court for the District of Delaware on 4 April 2023, disclosed under Item 1.03 of an 8-K that also disclosed $74.1 million in proposed debtor-in-possession financing. In a separate 8-K filed 10 April 2023, Virgin Orbit disclosed under Item 3.01 that Nasdaq had notified the company on 4 April 2023 that its securities would be suspended from trading "at the opening of business on April 13, 2023," citing Nasdaq Listing Rules 5101, 5110(b), IM-5101-1, and 5250(c)(1). The filing states the company intended to appeal the determination but that the appeal "will not impact the upcoming suspension of trading."

What the documents establish

The two 8-Ks, read together, establish a sequence that runs opposite to a routine minimum-bid-price story: Nasdaq's notice followed the bankruptcy filing and cited the company's failure to timely file its annual Form 10-K, rather than opening a standard cure period tied to a depressed share price. Listing Rule 5250(c)(1), which the notice cites, addresses late periodic filings; IM-5101-1 and Rule 5101 concern Nasdaq's discretionary authority over companies whose financial condition or bankruptcy status calls continued listing into question. Unlike a minimum-bid-price deficiency notice, which typically carries a stated compliance period of 180 calendar days, this notice announced an imminent suspension with an appeal the company itself acknowledged would not stop it. Virgin Orbit's own filings do not state that a routine bid-price notice preceded this determination.

The operating read

Not every Nasdaq notice disclosed under Item 3.01 is the same kind of notice, and conflating a bankruptcy-triggered delisting determination with a standard compliance-period deficiency notice would misstate what happened here; this distinction matters for sequencing cause and effect correctly. This is an editorial reading: an operator monitoring a portfolio company's or counterparty's listing status should identify which specific Nasdaq rule is cited in an Item 3.01 disclosure before assuming a standard cure period applies, since the rules cited here carry no such period.

What to check before you decide

Before assuming a Nasdaq notice follows the routine bid-price cure-period pattern, check the specific rule cited:

• Does the Item 3.01 disclosure cite a minimum bid price or equity standard, or a different rule tied to bankruptcy or late filing?
• Is a stated compliance period attached to the notice, or does the filing describe an immediate or near-term suspension instead?
• Did a bankruptcy filing or other Item 1.03 disclosure precede the Nasdaq notice, reversing the sequence a reader might otherwise assume?

Virgin Orbit's own filings record a bankruptcy petition on 4 April 2023 and a Nasdaq suspension notice citing that bankruptcy and a late 10-K, disclosed six days later. They do not record an earlier, separate bid-price deficiency notice with its own cure period.